Anti-Phospho-PKA C-alpha (PRKACA)-S339 Polyclonal Antibody for WB, IP, ELISA - P17612

Core Product Specifications and Parameters

Biological Background: PKA C-alpha (PRKACA) Function and Localization

• PKA C-alpha (PRKACA) is the catalytic subunit of cAMP-dependent protein kinase, with ubiquitous isoform 1 and sperm-specific isoform 2, the latter enriched in pachytene spermatocytes.
• It phosphorylates a vast array of substrates in the cytoplasm and nucleus, including histone H1.4, NFKB1, CDC25B, ABL1, VASP, and GLI transcription factors, thereby controlling processes such as transcriptional regulation, cell cycle progression, and platelet aggregation. Related references: PMID:15642694 PMID:15905176 PMID:16387847 PMID:15178447
• PRKACA acts as a critical inhibitor of the hedgehog signaling pathway by phosphorylating GLI1/2/3 and OFD1, which promotes processing and prevents transcriptional activation of target genes. Related references: PMID:16705181 PMID:33934390 PMID:36202993 PMID:39138140
• It negatively regulates mTORC1 signaling through phosphorylation of RPTOR, and also modulates calcium signaling via phosphorylation of RYR2. Related references: PMID:31112131 PMID:17693412
• In reproductive physiology, isoform 2 phosphorylates ABL1 in the sperm flagellum to promote capacitation, while in oocytes, PRKACA prevents meiotic resumption by inactivating CDC25B.
• Subcellularly, it localizes to the cytoplasm, nucleus, cell membrane, mitochondria, cilia, flagellum, and secretory vesicles, reflecting its pleiotropic roles in signaling compartmentalization.
• Pathogenic mutations in PRKACA are associated with Cushing syndrome, and the kinase is implicated in cancer through regulation of tight junctions and anti-invasive effects.
• The protein contains cAMP- and ATP-binding domains, a myristoylation site for membrane anchoring, and multiple phosphorylation sites that regulate its activity and interactions.

Experimental Guidance and Technical Tips

• The antibody targets phosphorylated S339 of PRKACA. To confirm specificity for the phosphorylated form, consider using phosphatase-treated cell lysates or competitive blocking with the non-phosphorylated peptide antigen.
• For Western blotting, a band at approximately 41 kDa is expected in human samples. Optimization of blocking conditions and antibody dilution is recommended to reduce background.
• In immunoprecipitation (IP) and ELISA, validate antibody performance in your specific sample matrix and consider cross-reactivity with other PKA isoforms if using non-human species.

CamelBio: Your One-Stop Sourcing Bridge

• CamelBio streamlines IVD raw-material procurement for diagnostic manufacturers and research laboratories, offering a comprehensive portfolio including this phospho-specific PKA C-alpha antibody for cAMP signaling and kinase research. Beyond single reagents, we provide validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and custom sourcing of rare targets to accelerate your assay development from concept to clinic.